Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,621
archived clinical trials in
Urology

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
407
mi
from
Denver, CO
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
407
mi
from
Denver, CO
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
425
mi
from
Longmont, CO
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
425
mi
from
Longmont, CO
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1337
mi
from
Waterbury, CT
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1337
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1315
mi
from
Aventura, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1315
mi
from
Aventura, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1105
mi
from
Clearwater, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1105
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1207
mi
from
Fort Myers, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1207
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1320
mi
from
Miami, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1320
mi
from
Miami, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1080
mi
from
Ocala, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1080
mi
from
Ocala, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1302
mi
from
Pembroke Pines, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1302
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1145
mi
from
Sarasota, FL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1145
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
801
mi
from
Atlanta, GA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
600
mi
from
Melrose Park, IL
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
600
mi
from
Melrose Park, IL
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
643
mi
from
Indianapolis, IN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
658
mi
from
Jeffersonville, IN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
658
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
568
mi
from
Newburgh, IN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
568
mi
from
Newburgh, IN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
723
mi
from
Lexington, KY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
723
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1308
mi
from
Albany, NY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1308
mi
from
Albany, NY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1291
mi
from
Kingston, NY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1291
mi
from
Kingston, NY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1294
mi
from
Poughkeepsie, NY
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1294
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
908
mi
from
Salisbury, NC
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
908
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
971
mi
from
Winston-Salem, NC
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
971
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1379
mi
from
Springfield, OR
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1379
mi
from
Springfield, OR
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1221
mi
from
Bala Cynwyd, PA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1221
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1167
mi
from
Lancaster, PA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1167
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1218
mi
from
Sellersville, PA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1218
mi
from
Sellersville, PA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1424
mi
from
Providence, RI
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1424
mi
from
Providence, RI
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
890
mi
from
Simpsonville, SC
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
890
mi
from
Simpsonville, SC
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
618
mi
from
Nashville, TN
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
618
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
340
mi
from
Dallas, TX
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
340
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1113
mi
from
Richmond, VA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
1408
mi
from
Tacoma, WA
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
1408
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated:  1/19/2017
GSK Investigational Site
mi
from
Surrey,
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status: Enrolling
Updated: 1/19/2017
GSK Investigational Site
mi
from
Surrey,
Click here to add this to my saved trials
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated:  1/25/2017
Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
Health Interventions in Men Undergoing Radical Prostatectomy
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Status: Enrolling
Updated: 1/25/2017
Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Diagnostic Challenges in IC (and Male CPPS)
Diagnostic Challenges in IC (and Male CPPS)
Status: Enrolling
Updated:  2/2/2017
Beth Israel Deaconess Medical Center
1444
mi
from
Boston, MA
Diagnostic Challenges in IC (and Male CPPS)
Diagnostic Challenges in IC (and Male CPPS)
Status: Enrolling
Updated: 2/2/2017
Beth Israel Deaconess Medical Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Linkage Analysis in Interstitial Cystitis
Genetic Studies of Urologic Chronic Pelvic Pain Syndrome
Status: Enrolling
Updated:  2/2/2017
Jordan D Dimitrakoff
1444
mi
from
Boston, MA
Linkage Analysis in Interstitial Cystitis
Genetic Studies of Urologic Chronic Pelvic Pain Syndrome
Status: Enrolling
Updated: 2/2/2017
Jordan D Dimitrakoff
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Status: Enrolling
Updated:  2/23/2017
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Status: Enrolling
Updated: 2/23/2017
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Status: Enrolling
Updated:  2/23/2017
Univ of Rochester Medical Center
1121
mi
from
Rochester, NY
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Status: Enrolling
Updated: 2/23/2017
Univ of Rochester Medical Center
1121
mi
from
Rochester, NY
Click here to add this to my saved trials
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Status: Enrolling
Updated:  2/23/2017
Whitney Loring
617
mi
from
Nashville, TN
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism
Status: Enrolling
Updated: 2/23/2017
Whitney Loring
617
mi
from
Nashville, TN
Click here to add this to my saved trials
Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Status: Enrolling
Updated:  2/28/2017
Loyola Univ Med Cntr - Dept of urology & obstetrics / Gynecology
601
mi
from
Maywood, IL
Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Status: Enrolling
Updated: 2/28/2017
Loyola Univ Med Cntr - Dept of urology & obstetrics / Gynecology
601
mi
from
Maywood, IL
Click here to add this to my saved trials
Precise Transvaginal Tape Placement Trial
Precise Transvaginal Tape Placement Trial
Status: Enrolling
Updated:  2/28/2017
Loyola University Health System
600
mi
from
Maywood, IL
Precise Transvaginal Tape Placement Trial
Precise Transvaginal Tape Placement Trial
Status: Enrolling
Updated: 2/28/2017
Loyola University Health System
600
mi
from
Maywood, IL
Click here to add this to my saved trials
Real World Data on Management of Male LUTS
Real World Data Exploring the Practices of Primary Care Providers in the Managment of Male Lower Urinary Tract Symptoms
Status: Enrolling
Updated:  3/8/2017
1245.23.10148 Boehringer Ingelheim Investigational Site
725
mi
from
Lexington, KY
Real World Data on Management of Male LUTS
Real World Data Exploring the Practices of Primary Care Providers in the Managment of Male Lower Urinary Tract Symptoms
Status: Enrolling
Updated: 3/8/2017
1245.23.10148 Boehringer Ingelheim Investigational Site
725
mi
from
Lexington, KY
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
1155
mi
from
Annapolis, MD
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
1155
mi
from
Annapolis, MD
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
574
mi
from
Sartell, MN
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
574
mi
from
Sartell, MN
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
475
mi
from
Southaven, MS
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
475
mi
from
Southaven, MS
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
645
mi
from
Bismarck, ND
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
645
mi
from
Bismarck, ND
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
1143
mi
from
San Diego, CA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
1143
mi
from
San Diego, CA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
1182
mi
from
Tarzana, CA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
1182
mi
from
Tarzana, CA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
1178
mi
from
Torrance, CA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
1178
mi
from
Torrance, CA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
409
mi
from
Denver, CO
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
409
mi
from
Denver, CO
Click here to add this to my saved trials